Mayne Pharma Group Limited (MAYNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mayne Pharma Group Limited (MAYNF) trades at $1.65 with AI Score 43/100 (Grade C). Mayne Pharma Group Limited is a specialty pharmaceutical company focused on manufacturing and distributing branded and generic products across multiple regions. Market cap: $134.06M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for MAYNF: MAYNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MAYNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MAYNF: the 1 perspectives are evenly split.
How is this calculated? →Mayne Pharma Group Limited (MAYNF) Healthcare & Pipeline Overview
Mayne Pharma Group Limited, based in Australia, develops, manufactures, and markets pharmaceutical products globally. With a focus on oral drug delivery and specialty areas like dermatology and women's health, the company operates through four segments, including contract services and international distribution, facing competition in the general drug manufacturing sector.
What Is the Investment Thesis for MAYNF?
Mayne Pharma Group Limited presents a complex investment case. With a market capitalization of $134.06M and a negative P/E ratio of -2.24, the company's profitability is a concern, evidenced by a negative profit margin of -20.4%. However, a gross margin of 54.8% indicates potential in operational efficiency. Key value drivers include the Metrics Contract Services segment and international expansion. Growth catalysts involve new product launches and strategic partnerships. Potential risks include regulatory challenges, competition from generic manufacturers, and the company's ability to achieve sustained profitability. Investors should closely monitor the company's financial performance and strategic initiatives.
Based on FMP financials and quantitative analysis
MAYNF Key Highlights
- Market capitalization of $134.06M indicates its size relative to competitors.
- Negative P/E ratio of -2.24 reflects current unprofitability.
- Profit margin of -20.4% highlights operational challenges.
- Gross margin of 54.8% suggests potential for profitability with improved cost management.
- Beta of 0.98 indicates volatility similar to the overall market.
Who Are MAYNF's Competitors?
MAYNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| BHCCF Benchmark Holdings plc | $0.37 | +0.00% | $225.11M | 41 |
| CPHRF Cipher Pharmaceuticals Inc. | $11.94 | +1.49% | $303.17M | 63 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $13.90 | +3.08% | $4.47B | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MAYNF's Key Strengths?
- Diverse product portfolio across branded and generic pharmaceuticals.
- Global presence with operations in multiple regions.
- Established manufacturing capabilities.
- Contract services segment provides a stable revenue stream.
What Are MAYNF's Weaknesses?
- Negative profit margin indicates financial challenges.
- High debt levels may constrain growth opportunities.
- Dependence on key products and markets.
- Exposure to regulatory risks and pricing pressures.
What Could Drive MAYNF Stock Higher?
- Potential new product launches in dermatology and women's health.
- Expansion of Metrics Contract Services through new partnerships.
- Geographic expansion into emerging markets.
- Regulatory approvals for key pipeline products.
- Cost optimization initiatives to improve profitability.
What Are the Key Risks for MAYNF?
- Financial-distress signal — its Altman Z-Score of -0.59 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-23.0%) — the business is not currently generating profit on shareholder capital.
- Intense competition from generic and branded pharmaceutical companies.
- Regulatory changes and pricing pressures.
- Product liability claims and recalls.
- Negative profit margin indicates financial challenges.
- High debt levels may constrain growth opportunities.
What Are the Growth Opportunities for MAYNF?
- Expansion of Metrics Contract Services: Mayne Pharma can leverage its Metrics Contract Services segment to drive growth by securing additional contracts with pharmaceutical companies seeking development, manufacturing, and analytical services. The global pharmaceutical contract manufacturing market is projected to reach $227.7 billion by 2028, presenting a significant opportunity for Mayne Pharma to increase its market share. This expansion can be achieved through targeted marketing and strategic partnerships.
- New Product Development and Launches: Mayne Pharma can invest in research and development to create and launch new branded and generic pharmaceutical products. Focusing on therapeutic areas with unmet needs, such as dermatology and women's health, can drive revenue growth. Successful product launches require regulatory approvals and effective marketing strategies. The timeline for new product development varies depending on the complexity of the drug and regulatory requirements.
- Geographic Expansion: Mayne Pharma can expand its presence in existing markets and enter new geographic regions to increase its customer base and revenue streams. Focusing on emerging markets with growing healthcare expenditures can provide significant growth opportunities. This expansion requires careful market analysis, regulatory compliance, and strategic partnerships with local distributors. The timeline for geographic expansion depends on the specific market and regulatory environment.
- Strategic Acquisitions: Mayne Pharma can pursue strategic acquisitions to expand its product portfolio, geographic reach, and manufacturing capabilities. Acquiring companies with complementary products or technologies can create synergies and drive revenue growth. Successful acquisitions require careful due diligence and integration planning. The timeline for acquisitions depends on the size and complexity of the target company.
- Partnerships and Collaborations: Mayne Pharma can form partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to develop and commercialize new products and technologies. These partnerships can provide access to new markets, expertise, and resources. Successful partnerships require clear agreements and effective communication. The timeline for partnerships depends on the specific project and objectives.
What Opportunities Does MAYNF Have?
- Expansion into new therapeutic areas.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Increased demand for generic drugs in emerging markets.
- Partnerships with other pharmaceutical companies and research institutions.
What Threats Does MAYNF Face?
- Intense competition from generic and branded pharmaceutical companies.
- Regulatory changes and pricing pressures.
- Product liability claims and recalls.
- Economic downturns and currency fluctuations.
What Are MAYNF's Competitive Advantages?
- Proprietary oral drug delivery systems offer a technological advantage.
- Established manufacturing capabilities provide a barrier to entry.
- Global distribution network enables access to multiple markets.
- Contract services segment provides a diversified revenue stream.
What Does MAYNF Do?
Mayne Pharma Group Limited, originally Halcygen Pharmaceuticals Limited, was founded in 2005 and rebranded in 2010. Headquartered in Salisbury South, Australia, the company operates as a specialty pharmaceutical manufacturer and distributor with a global reach, including Australia, New Zealand, the United States, Canada, Europe, and Asia. The company's business is divided into four key segments: Metrics Contract Services, which provides pharmaceutical development, manufacturing, and analytical services; International, which handles distribution in various global markets; Branded Products, focusing on proprietary pharmaceuticals; and Portfolio Products, encompassing a range of established medications. Mayne Pharma specializes in oral drug delivery systems and offers a diverse portfolio of generic and branded products in therapeutic areas such as dermatology, women's health, and infectious diseases. The company aims to leverage its manufacturing capabilities and global presence to deliver pharmaceutical solutions to patients and healthcare providers.
What Products and Services Does MAYNF Offer?
- Manufactures and sells branded pharmaceutical products.
- Manufactures and sells generic pharmaceutical products.
- Provides oral drug delivery systems.
- Offers contract pharmaceutical development services.
- Offers contract pharmaceutical manufacturing services.
- Provides contract pharmaceutical analytical services.
- Distributes specialty pharmaceutical products in dermatology.
- Distributes specialty pharmaceutical products in women's health and infectious diseases.
How Does MAYNF Make Money?
- Develops and manufactures generic and branded pharmaceuticals.
- Generates revenue through product sales in various geographic markets.
- Provides contract services to third-party pharmaceutical companies.
- Focuses on specialty therapeutic areas such as dermatology and women's health.
What Industry Does MAYNF Operate In?
Mayne Pharma operates within the competitive drug manufacturing industry, facing pressure from both generic and branded pharmaceutical companies. The industry is characterized by stringent regulatory requirements, intense research and development, and pricing pressures. Market trends include increasing demand for generic drugs, advancements in drug delivery technologies, and a growing focus on specialty pharmaceuticals. Mayne Pharma's focus on oral drug delivery systems and contract services positions it to capitalize on these trends, but it must navigate the competitive landscape and regulatory hurdles to achieve sustainable growth.
Who Are MAYNF's Key Customers?
- Patients who use their branded and generic pharmaceutical products.
- Hospitals and clinics that prescribe or administer their products.
- Pharmacies that dispense their medications.
- Third-party pharmaceutical companies utilizing their contract services.
ROE -23%Key Financial Metrics
Return on equity for Mayne Pharma Group Limited stands at -23.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -8.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.2%, the inverse of the P/E and a quick read on earnings relative to price.
Mayne Pharma Group Limited (MAYNF) Valuation Context
Valued at $134.06M, MAYNF is classified as a micro-cap stock. Relative to its peer group, MAYNF's quantitative score of 43/100 is below the peer average of 56/100.
Company Profile
Mayne Pharma Group Limited operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Salisbury South, AU. The company is led by CEO Aaron Gray. MAYNF has traded publicly since 2013.
F-Score 5/9Financial Health
Mayne Pharma Group Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.59 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Mayne Pharma Group Limited revenue of about $402.0M for fiscal 2026, with EPS near $-0.43.
MAYNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio across branded and generic pharmaceuticals.
- Global presence with operations in multiple regions.
- Established manufacturing capabilities.
- Contract services segment provides a stable revenue stream.
Bear Case
- Negative profit margin indicates financial challenges.
- High debt levels may constrain growth opportunities.
- Dependence on key products and markets.
- Exposure to regulatory risks and pricing pressures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MAYNF Latest News
-
3 ASX Penny Stocks With Market Caps Over A$70M To Consider
Yahoo! Finance: MAYNF News · May 22, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
MAYNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MAYNF.
Price Targets
Wall Street price target analysis for MAYNF.
MAYNF MoonshotScore
What does this score mean?
The MoonshotScore rates MAYNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Aaron Gray
Unknown
Information on Aaron Gray's background is limited. He currently manages 450 employees at Mayne Pharma Group Limited. Further details regarding his career history, education, and previous roles are not available in the provided data.
Track Record: Due to limited information, Aaron Gray's key achievements, strategic decisions, and company milestones under his leadership cannot be assessed. Additional data is needed to evaluate his track record at Mayne Pharma Group Limited.
MAYNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mayne Pharma Group Limited (MAYNF) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting, leading to increased risks for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. The lack of stringent requirements can result in less transparency and potentially greater price volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in exiting positions.
- OTC Other tier companies may have a higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to exchange-listed companies.
- Potential for delisting or trading suspension due to non-compliance.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and debt levels.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation since 2005.
- Operates in the regulated pharmaceutical industry.
- Has a global presence with operations in multiple regions.
- Employs 450 people.
What Investors Ask About Mayne Pharma Group Limited (MAYNF) — Healthcare
What does Mayne Pharma Group Limited do?
Mayne Pharma Group Limited is a specialty pharmaceutical company that develops, manufactures, and markets a range of branded and generic pharmaceutical products. It operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. The company provides oral drug delivery systems and contract pharmaceutical development, manufacturing, and analytical services. Mayne Pharma distributes specialty pharmaceutical products in therapeutic areas such as dermatology, women's health, and infectious diseases across Australia, New Zealand, the United States, Canada, Europe, and Asia.
What are the main risks for MAYNF?
Mayne Pharma faces several risks inherent to the pharmaceutical industry, including intense competition from both generic and branded drug manufacturers. Regulatory changes and pricing pressures can impact revenue and profitability. Product liability claims and recalls pose a threat to the company's reputation and financial performance. The company's negative profit margin and high debt levels also present financial challenges. Investing in an OTC stock like MAYNF carries additional risks related to liquidity and transparency.
What are the key factors to evaluate for MAYNF?
Mayne Pharma Group Limited (MAYNF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does MAYNF data refresh on this page?
MAYNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MAYNF's recent stock price performance?
Mayne Pharma Group Limited (MAYNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across branded and generic pharmaceuticals. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MAYNF overvalued or undervalued right now?
Valuing Mayne Pharma Group Limited (MAYNF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MAYNF?
Before investing in Mayne Pharma Group Limited (MAYNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MAYNF to a portfolio?
Key strength of Mayne Pharma Group Limited (MAYNF): Diverse product portfolio across branded and generic pharmaceuticals. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- CEO background information is limited.